A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (NCT07222488)
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Who can join: Review the eligibility criteria below.
Location: Michael G Oefelein Clinical Trials ( Site 0005) — Bakersfield, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Michael G Oefelein Clinical Trials ( Site 0005) — Bakersfield, California
- Rutgers Cancer Institute of New Jersey ( Site 0007) — New Brunswick, New Jersey
- Carolina Urologic Research Center ( Site 0006) — Myrtle Beach, South Carolina
- Medizinische Universität Wien ( Site 0021) — Vienna, State of Vienna
- UZ Gent ( Site 0031) — Ghent, Oost-Vlaanderen
- CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011) — Québec, Quebec
- Gustave Roussy ( Site 0041) — Villejuif, Val-de-Marne
- European Interbalkan Medical Center ( Site 0051) — Thessaloniki,
- Rabin Medical Center ( Site 0062) — Petah Tikva,
- Centro Ricerche Cliniche di Verona ( Site 0072) — Verona, Veneto
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081) — Amsterdam, North Holland
- Akershus Universitetssykehus ( Site 0091) — Lorenskog, Akershus
- Hospital Universitario Virgen de la Victoria ( Site 0111) — Málaga, Andalusia
- Hospital Universitario 12 de Octubre ( Site 0112) — Madrid, Madrid, Comunidad de
- Ankara University Health Practice and Research Hospitals ( Site 0132) — Ankara,
- Koc Universitesi Hastanesi ( Site 0133) — Istanbul,
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Bladder Cancer
- Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer — St Louis, Missouri
- Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer — Calgary, Alberta
- Determinants of Bladder Cancer Recurrence Study (The DETER Study) — Basking Ridge, New Jersey
- Quality of Life in Patients With Bladder Cancer — New York, New York
- A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer — Hartford, Connecticut
- A Diagnostic for the Early Detection of Bladder Cancer — Long Beach, California
Explore by condition: All Bladder Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.